A photo of David Hildeman.

Director, Immunology Graduate Program

Professor, UC Department of Pediatrics

513-636-3923

513-636-5355

Biography & Affiliation

Biography

My lab is interested in understanding mechanisms underlying lymphocyte development, homeostasis and function. We are studying these processes in the context of aging, infection and vaccination as well as transplant rejection.

Our long-term goal is to identify molecular mechanisms that can be exploited to boost immunity, such as vaccine responsiveness. The mechanisms could also be manipulated to decrease auto-immunity or allo-immunity like autoimmune disease, transplant rejection or allergic reactions.

One of the reasons I love doing immunology research is because I learn new things about the complexity of the immune system and how it has developed to provide protective immunity while avoiding autoimmunity. Beyond the outstanding research environment, phenomenal PhD program, and the cutting-edge core facilities, another reason for doing research at the Cincinnati Children’s Hospital Medical Center is the collaborative environment.

For example, our work on aging has been a close collaboration between my lab and Dr. Claire Chougnet’s lab. Furthermore, our research in transplantation started as the result of a phone call from a world-renowned transplant surgeon at the University of Cincinnati about joining forces on T-cell mediated kidney rejection.

One of the most notable findings my team and I have uncovered includes a function for the pro-apoptotic molecule Bim in driving the “crash” of T-cells after the pinnacle of an immune response. We also discovered a common gamma chain cytokine/STAT5/Bcl2 network that antagonizes Bim and is needed for developing protective T-cell memory.

I am a Fellow of the Graduate School at the University of Cincinnati, the PI of a T32 Training Grant, and served as a permanent member of the Cellular and Molecular Immunology-B National Institutes of Health (NIH) study section as well as Chair of several NIH study sections.

I have more than 20 years of experience in the immunology field and started working at Cincinnati Children’s Hospital Medical Center in 2002. My research has been published in many journals, including PNAS, Science Advances, Cell Death and Differentiation, and American Journal of Transplantation.

Clinical Interests

T cells; autoimmunity; sex differences in immune responses; apoptosis

Research Interests

Molecular factors that control the decision between tolerance and immunity within T lymphocytes; staphylococcal enterotoxins, recombinant vaccinia viruses, lymphocytic choriomeningitis virus and MHC tetrameric reagents; antigen -specific T cell responses; tolerance centers on regulation of mechanisms that control the survival and death of activated T cells in vivo, namely Bcl-2 and its antagonist Bim; manipulation and regulation of antigen-specific T cell responses via novel vaccine strategies to either induce tolerance or enhance immunity; mechanisms underlying sex-based differences in T cell responses and how these differences relate to autoimmune disease.

Academic Affiliation

Professor, UC Department of Pediatrics

Divisions

Fibrosis, Immunobiology



Blog Posts

New Concept for Boosting Flu Vaccine Power Also Might Apply to Future COVID-19 Vaccines

Infectious Diseases and Vaccines

New Concept for Boosting Flu Vaccine Power Also Might Apply to Future COVID-19 Vaccines

David A. Hildeman, PhD7/29/2020

Education

PhD: University of Wisconsin-Madison, Madison, Wisconsin, 1997.

Publications

Plasma cell targeting to prevent antibody-mediated rejection. Woodle, ES; Tremblay, S; Rossi, A; Rojas, CC; Alloway, R; Roskin, K; Allman, D; Hildeman, D. American Journal of Transplantation. 2020; 20 Suppl 4:33-41.

mTOR Inhibitor Therapy Diminishes Circulating CD8+ CD28- Effector Memory T Cells and Improves Allograft Inflammation in Belatacept-refractory Renal Allograft Rejection. Castro-Rojas, CM; Godarova, A; Shi, T; Hummel, SA; Shields, A; Tremblay, S; Alloway, RR; Jordan, MB; Woodle, ES; Hildeman, DA. Transplantation. 2020; 104:1058-1069.

T-cell receptor signal strength and epigenetic control of Bim predict memory CD8+ T-cell fate. Li, K; Ladle, BH; Kurtulus, S; Sholl, A; Shanmuganad, S; Hildeman, DA. Cell Death and Differentiation. 2020; 27:1214-1224.

The Variable Genomic NK Cell Receptor Locus Is a Key Determinant of CD4+ T Cell Responses During Viral Infection. Raynor, J; Lin, A; Hummel, SA; Lampe, K; Jordan, M; Hoebe, K; Hildeman, DA. Frontiers in Immunology. 2020; 11.

A prospective, iterative, adaptive trial of carfilzomib-based desensitization. Tremblay, S; Driscoll, JJ; Rike-Shields, A; Hildeman, DA; Alloway, RR; Girnita, AL; Brailey, PA; Woodle, ES. American Journal of Transplantation. 2020; 20:411-421.

Tubular cell and keratinocyte single-cell transcriptomics applied to lupus nephritis reveal type I IFN and fibrosis relevant pathways. Der, E; Suryawanshi, H; Morozov, P; Kustagi, M; Goilav, B; Ranabathou, S; Izmirly, P; Clancy, R; Belmont, HM; Koenigsberg, M; et al. Nature Immunology. 2019; 20:915-927.

The immune cell landscape in kidneys of patients with lupus nephritis. Arazi, A; Rao, DA; Berthier, CC; Davidson, A; Liu, Y; Hoover, PJ; Chicoine, A; Eisenhaure, TM; Jonsson, AH; Li, S; et al. Nature Immunology. 2019; 20:902-914.

High Dimensional Renal Profiling: Towards a Better Understanding or Renal Transplant Immune Suppression. Castro-Rojas, CM; Alloway, RR; Woodle, ES; Hildeman, DA. Current Transplantation Reports. 2019; 6:60-68.

Olfactomedin 4 marks a subset of neutrophils in mice. Alder, MN; Mallela, J; Opoka, AM; Lahni, P; Hildeman, DA; Wong, HR. Innate Immunity. 2019; 25:22-33.

Gimap5-dependent inactivation of GSK3 beta is required for CD4(+) T cell homeostasis and prevention of immune pathology. Patterson, AR; Endale, M; Lampe, K; Aksoylar, HI; Flagg, A; Woodgett, JR; Hildeman, D; Jordan, MB; Singh, H; Kucuk, Z; et al. Nature Communications. 2018; 9.